Revenue Breakdown
Composition ()
No data
Revenue Streams
Aktis Oncology Inc (AKTS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is RF Filters, accounting for 57.1% of total sales, equivalent to $3.34M. Another important revenue stream is Foundry Fabrication Services. Understanding this composition is critical for investors evaluating how AKTS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Aktis Oncology Inc maintains a gross margin of 47.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.11%, while the net margin is -71.12%. These profitability ratios, combined with a Return on Equity (ROE) of -11970.59%, provide a clear picture of how effectively AKTS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AKTS competes directly with industry leaders such as MLTX and SEPN. With a market capitalization of $1.08B, it holds a significant position in the sector. When comparing efficiency, AKTS's gross margin of 47.66% stands against MLTX's N/A and SEPN's 100.00%. Such benchmarking helps identify whether Aktis Oncology Inc is trading at a premium or discount relative to its financial performance.
